An experimental injection called CBL-514 has shown promise in phase 2 clinical trials by triggering apoptosis in fat cells, significantly reducing deep abdominal visceral and subcutaneous fat. Highlighted at the European Association for the Study of Diabetes annual meeting in Milan, the treatment co